NCT06032728Not yet recruiting
Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on Multimodal Recurrence Scoring System
Source: ClinicalTrials.gov · Last updated 13 Sept 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive adjuvant targeted therapy or not is still on debate. The investigators invented a multimodal recurrence scoring system that was successfully categorise patients with stage III clear cell renal cell carcinoma into high-risk and low-risk groups with Hazard Ratio (HR) of 6.21. Here the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC into adjuvant targeted therapy group and observation group. Disease free survival and overall survival are the end points of observation.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 488 (estimated)
- First submitted
- 30 Aug 2023
- Start date
- 1 Oct 2023
- Primary completion date
- 1 Oct 2033
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Diseases
- Kidney cancer
- NCT number
- NCT06032728
What you commit to
- Study type: Interventional
- Planned participants: 488
- From 1 Oct 2023 to the primary completion date, 1 Oct 2033
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously received neoadjuvant therapy
- With contraindication to receive adjuvant targeted therapy.
Other illness
- With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
Other
- With bad compliance or contraindication to enrollment.
- Pregnant woman or lactating woman.
Who the study is looking for
- The informed consent has been obtained from the patient.
- With confirmed diagnosis of stage III clear cell renal cell carcinoma
- With moderate/good Eastern Cooperative Oncology Group (ECOG) health rating (PS): 0-1 score.
- The patient receive no anti-cancer treatment before primary surgery.
- The patient receive radical operation for renal cancer with negative margin.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.